MorphoSys Hits Refresh Button On Pipeline With Constellation Buy
Deal Worth $1.7bn Financed Through $2bn Partnership With Royalty
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
You may also be interested in...
The German biotech announced in March that it was terminating the early-stage oncology R&D projects that came with its purchase of Constellation last year and Novartis has snapped up one of them.
The company will close down early-stage research programs brought under its wing through last year’s acquisition of Constellation Pharmaceuticals.
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.